These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 8595515)
21. Current HIV clinical trial design issues. Lange JM J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S47-51. PubMed ID: 8595508 [TBL] [Abstract][Full Text] [Related]
22. [Anti-retroviral treatment of HIV infection in the child]. De José Gómez MI Allergol Immunopathol (Madr); 1998; 26(3):139-44. PubMed ID: 9675397 [TBL] [Abstract][Full Text] [Related]
23. Early antiretroviral therapy: rationale, protease inhibitor-sparing regimens and once daily dosing. Gatell JM Antivir Ther; 1998; 3 Suppl 4():49-53. PubMed ID: 10723510 [TBL] [Abstract][Full Text] [Related]
24. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure. Montroni M; Monforte AD Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591 [TBL] [Abstract][Full Text] [Related]
25. Emergence of HIV-1 drug resistance during antiretroviral treatment. Rong L; Feng Z; Perelson AS Bull Math Biol; 2007 Aug; 69(6):2027-60. PubMed ID: 17450401 [TBL] [Abstract][Full Text] [Related]
26. Current status and future issues in the treatment of HIV-1 infection. Matsushita S Int J Hematol; 2000 Jul; 72(1):20-7. PubMed ID: 10979204 [TBL] [Abstract][Full Text] [Related]
28. Drug failure and HIV resistance create frustrating scenarios for clinicians. Murphy MJ Fac Notes (New Orleans La); 1998; 10(5):1-3. PubMed ID: 11365830 [TBL] [Abstract][Full Text] [Related]
29. New questions about therapy. Boston AIDS Writers Group. Surviv News (Atlanta Ga); 1998 May; ():19-20. PubMed ID: 11365366 [TBL] [Abstract][Full Text] [Related]
30. Was there a homerun in DC? Reports from a retrovirus conference generate real excitement. McGuire S Posit Aware; 1996; 7(2):20-2. PubMed ID: 11363361 [TBL] [Abstract][Full Text] [Related]
31. [Treatment strategies and surveillance of chronic HIV infection in adults]. Joly V; Yeni P Rev Prat; 1999 Oct; 49(16):1773-80. PubMed ID: 10578608 [TBL] [Abstract][Full Text] [Related]
32. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. Fischl MA AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785 [TBL] [Abstract][Full Text] [Related]
33. [Salvage therapy for HIV infection]. Salzberger B MMW Fortschr Med; 2005 Apr; 147 Spec No 1():32-7. PubMed ID: 16385870 [TBL] [Abstract][Full Text] [Related]
34. Protease inhibitors: implications for HIV research and treatment. Churchill SA J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):13-8. PubMed ID: 11363325 [TBL] [Abstract][Full Text] [Related]
35. Treatment interruptions in HIV-infected subjects. Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398 [TBL] [Abstract][Full Text] [Related]
36. Advances in the medical management of patients with HIV-1 infection: an overview. Volberding PA AIDS; 1999 Sep; 13 Suppl 1():S1-9. PubMed ID: 10546780 [TBL] [Abstract][Full Text] [Related]
37. AIDS pathogenesis: from models to viral dynamics in patients. Nowak MA J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S1-5. PubMed ID: 8595501 [TBL] [Abstract][Full Text] [Related]
38. Combination therapy: more effective control of HIV type 1? Johnson VA AIDS Res Hum Retroviruses; 1994 Aug; 10(8):907-12. PubMed ID: 7811541 [TBL] [Abstract][Full Text] [Related]
39. Treatment research priorities for human immunodeficiency virus infection. Pettinelli CB; Schnittman SM Infect Agents Dis; 1993 Oct; 2(5):291-303. PubMed ID: 8173814 [TBL] [Abstract][Full Text] [Related]
40. HIV-1 burden as a marker of disease progression and clinical response to therapy in AIDS. Coombs RW Clin Lab Med; 1994 Jun; 14(2):301-11. PubMed ID: 7924193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]